SUSTAIN-6 — CV Outcomes in T2DM

Source: New England Journal of Medicine (2016).

Key finding: 26% reduction in MACE.

Part of GLP1Score's 20-study clinical evidence library — the peer-reviewed research powering our GLP-1 eligibility scoring engine.

Related Reading

Semaglutide in India — Complete Guide
Semaglutide Drug Monograph (dosing, contraindications)
Who Qualifies for Semaglutide in India
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)
Semaglutide 2.4 mg for Weight Management in Overweight or Obese Adults with Type 2 Diabetes (STEP 2)
Metabolic Non-Communicable Disease Health Report of India: The ICMR-INDIAB National Cross-Sectional Study (INDIAB-17)

Take the Free Eligibility Assessment → · Compare All 18+ Brands